---
canonical_name: Palmitoylethanolamide
alternate_names: PEA, Palmidrol, N-palmitoylethanolamine, N-(2-hydroxyethyl)hexadecanamide, Micronized Palmitoylethanolamide, m-PEA, Ultramicronized Palmitoylethanolamide, um-PEA, Impulsin, Normast, PeaPure, Levagen+
canonical_topic: Palmitoylethanolamide for Health & Longevity
short_topic_lc: palmitoylethanolamide
creation_date: 2026-0928-0004
creator_ai_fullname: Opus 5.5
---

# Palmitoylethanolamide for Health & Longevity
<section id="top" markdown="1"></section>  
Evidence Review created on 09/28/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5.5  

**Also known as:** PEA, Palmidrol, N-palmitoylethanolamine, N-(2-hydroxyethyl)hexadecanamide, Micronized Palmitoylethanolamide, m-PEA, Ultramicronized Palmitoylethanolamide, um-PEA, Impulsin, Normast, PeaPure, Levagen+

  

## Motivation

<!-- Author statement: This Motivation section was written only after all other sections of the review were completed, so that it reflects the full scope of the topic. -->

Palmitoylethanolamide (PEA) is a fatty molecule that the body makes on demand in nearly every tissue, especially when cells are stressed or injured. It belongs to the same family of signaling fats as the body's own cannabis-like messengers, but it is not intoxicating. Its main role appears to be calming overactive immune cells, which makes it a candidate for problems driven by persistent, low-grade inflammation.

Small amounts occur naturally in egg yolk, soybeans and peanuts. A drug version was sold in Czechoslovakia in the 1970s, and today the compound is sold as an over-the-counter supplement in many countries and as a special medical food in Italy. Interest from health-focused adults centers on long-lasting pain, brain health and the slow build-up of inflammation with age.

This review examines the human evidence on palmitoylethanolamide used as an oral supplement: what it may do for pain, brain function and other aspects of health, what risks and gaps are known, how it is dosed, and how much of the research comes from the companies that sell it, so that its current standing is clear.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  

## Recommended Reading

This section lists expert commentary and narrative reviews that give a high-level overview of palmitoylethanolamide.

<!-- Author statement on the search: Real-time web searches (WebSearch) were run for "palmitoylethanolamide" and "PEA" combined with each priority expert, followed by on-site searches: foundmyfitness.com (one hit, the members-only episode "Q&A #31", whose public show notes mention only luteolin for post-COVID smell loss), peterattiamd.com (no results for "palmitoylethanolamide" or "PEA pain"), hubermanlab.com (hits only for phenylethylamine, a different compound also abbreviated PEA; a web search additionally found the episode page "Essentials: How to Control Your Sense of Pain & Pleasure", which lists a study of PEA with acetyl-L-carnitine for fibromyalgia among its show-note resources but offers no discussion of PEA itself), chriskresser.com (no results), lifespan.io (no articles) and lifeextension.com (several magazine articles on PEA). PubMed was searched for narrative reviews of palmitoylethanolamide pharmacology, clinical use and history. Items were selected for depth of coverage, independence of viewpoint and relevance. -->

* [Break the Cycle of Chronic Pain](https://www.lifeextension.com/magazine/2017/ss/break-the-cycle-of-chronic-pain) - Steven Dessange

  Life Extension Magazine feature explaining how PEA damps inflammation where pain arises and summarizing its pain trials; it pairs PEA with honokiol (a magnolia bark compound), and Life Extension sells both.

* [The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations](https://pubmed.ncbi.nlm.nih.gov/27539936/) - Petrosino & Di Marzo, 2017

  Review of PEA's receptor targets and micronized (ground to tiny particles) formulations by endocannabinoid (the body's cannabis-like signaling system) researchers; the first author was also affiliated with Epitech, which sells ultramicronized PEA.

* [Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy](https://pubmed.ncbi.nlm.nih.gov/27220803/) - Gabrielsson et al., 2016

  Independent critical appraisal from Umeå University showing how little is known about PEA absorption, questioning trial quality and noting that superiority of micronized forms is unproven.

* [Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold](https://pubmed.ncbi.nlm.nih.gov/24066256/) - Keppel Hesselink et al., 2013

  Revisits six 1970s trials in nearly 4,000 people that tested PEA against colds and flu, documenting the compound's largely forgotten first clinical career.

* [Palmitoylethanolamide: A Natural Compound for Health Management](https://pubmed.ncbi.nlm.nih.gov/34069940/) - Clayton et al., 2021

  Broad overview of PEA for immunity, brain health, joints, sleep and recovery; several authors work for Gencor, maker of the water-dispersible Levagen+ form, so it reflects an industry perspective.

Note on priority experts: no directly relevant content on palmitoylethanolamide was found from Rhonda Patrick (her only search hit is a members-only question-and-answer episode whose public notes discuss luteolin), Peter Attia, Andrew Huberman (his site's hits concern phenylethylamine, an unrelated compound also abbreviated PEA, apart from a pain episode that lists a PEA fibromyalgia study only as a show-note resource), Chris Kresser or Lifespan.io.

  

## Grokipedia

<!-- Author statement on the search: grokipedia.com was searched directly for "palmitoylethanolamide". d-browser: the site's search page (grokipedia.com/search?q=palmitoylethanolamide) returned "Failed to search. Please try again."; d-fetch: same message; d-proxy-1: same message; d-proxy-2: same message. The direct article URL grokipedia.com/page/Palmitoylethanolamide was then tried on every tier: d-browser returned "Article Not Found", d-fetch returned HTTP 404, d-proxy-1 returned "Article Not Found" and d-proxy-2 returned "Article not found – This article doesn't exist yet in Grokipedia." On re-check during QA on September 28, 2026, d-browser loaded the article "Palmitoylethanolamide" at grokipedia.com/page/Palmitoylethanolamide. -->

* [Palmitoylethanolamide](https://grokipedia.com/page/Palmitoylethanolamide)

  AI-generated encyclopedia entry covering PEA's chemistry, synthesis and breakdown, receptor targets, preclinical and clinical research, therapeutic uses and safety profile, with references to the underlying studies.

  

## Examine

<!-- Author statement on the search: examine.com was searched directly for "palmitoylethanolamide". d-browser: returned a "Vercel Security Checkpoint" bot wall; d-fetch: HTTP 429; d-proxy-1: returned the site's search results, whose first hit was the supplement page "Palmitoylethanolamide" (examine.com/supplements/palmitoylethanolamide/), which was then loaded and read via d-proxy-1. -->

* [Palmitoylethanolamide](https://examine.com/supplements/palmitoylethanolamide/)

  Examine's evidence page by Kamal Patel grades PEA's effect on pain at "B" and catalogs trials in dysmenorrhea (painful periods) and diabetic neuropathy (nerve damage from diabetes); outcome details require membership.

  

## ConsumerLab

<!-- Author statement on the search: consumerlab.com was searched directly for "palmitoylethanolamide". d-browser returned the site's search results on the first attempt, led by the CL Answer "What are the health benefits of palmitoylethanolamide (PEA), and is it safe?", which was then loaded via d-browser (latest update August 27, 2026). No further tiers were needed. -->

* [What are the health benefits of palmitoylethanolamide (PEA), and is it safe?](https://www.consumerlab.com/answers/palmitoylethanolamide-health-benefits-and-safety/pea/)

  ConsumerLab's answer, updated August 2026, reviews PEA for arthritis, nerve and menstrual pain, allergies and mood, covers absorption-enhancing formulations and names preferred products; most content requires membership.

  

## Systematic Reviews

This section lists systematic reviews and meta-analyses (studies that statistically pool the results of several trials) of palmitoylethanolamide in human clinical trials.

<!-- Author statement on the search: A real-time PubMed search was run on 2026-09-28 for: palmitoylethanolamide AND (systematic review[pt] OR meta-analysis[pt] OR "systematic review"[ti] OR "meta-analysis"[ti]), returning 37 records. Reviews limited to PEA-luteolin combinations, to animal data, or to broad drug classes were deprioritized. Selection prioritized relevance to oral PEA alone, number of included trials and patients, recency, and coverage of the main clinical claims. -->

* [Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials](https://pubmed.ncbi.nlm.nih.gov/36986081/) - Lang-Illievich et al., 2023

  Pooled 11 double-blind trials (774 patients); PEA lowered chronic pain scores versus comparators, and no major side effects were attributed to it.

* [Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding](https://pubmed.ncbi.nlm.nih.gov/39798151/) - Viña & López-Moreno, 2025

  Largest pooling to date: 18 randomized trials, 1,196 patients; benefit across nerve, tissue-injury and sensitization-type pain within 4–6 weeks.

* [Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/38892586/) - Schweiger et al., 2024

  Nine studies, 742 patients: pain kept falling during the second month, supporting courses of at least 60 days; mostly open-label (unblinded) Italian studies.

* [Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations](https://pubmed.ncbi.nlm.nih.gov/39839988/) - Bortoletto et al., 2025

  Maps 47 randomized trials across pain, mood, cognition, eye pressure and allergy; tolerability matched controls, but most trials were small and single-country.

* [Evaluation of the nutraceutical Palmitoylethanolamide in reducing intraocular pressure (IOP) in patients with glaucoma or ocular hypertension: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/38269580/) - Crupi et al., 2025

  Six studies, 199 patients: oral PEA lowered eye pressure in glaucoma (pressure-related optic nerve damage) and ocular hypertension (raised pressure alone).

No systematic review or meta-analysis is dedicated to the harms of palmitoylethanolamide; its principal risk side, safety and tolerability, is represented only within the efficacy reviews above.

  

## Mechanism of Action

PEA is released from membrane fats on demand when tissue is stressed, acts locally, and is then broken down. Its best-established target is PPAR-α (peroxisome proliferator-activated receptor alpha, a nuclear switch that turns down inflammatory genes and turns up fat burning); mice lacking this receptor lose PEA's anti-inflammatory effect ([Lo Verme et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15465922/)).

Additional proposed mechanisms:

* **Immune-cell calming:** PEA damps mast cells (immune cells that release histamine) and microglia (the brain's immune cells), the basis of its original label ALIA (autacoid local injury antagonism, a locally made brake on injury responses).
* **Entourage effect:** by competing for FAAH (fatty acid amide hydrolase, an enzyme that degrades cannabis-like messengers), PEA may raise anandamide (a cannabis-like messenger) and indirectly strengthen CB1 and CB2 (cannabinoid receptors 1 and 2) signaling.
* **Pain-sensing channels:** cell studies show activity at TRPV1 (a heat- and pain-sensing channel) and GPR55 (a lesser-known receptor linked to pain signaling).

Pharmacology: PEA is fat-soluble and poorly absorbed. After 300 mg of micronized PEA, plasma levels roughly doubled at 2 hours and were back to baseline by 4 hours; rat data suggest a half-life near 12 minutes ([Gabrielsson et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27220803/)). It is broken down by FAAH and NAAA (N-acylethanolamine acid amidase, the main PEA-degrading enzyme in immune cells), not by CYP (cytochrome P450, liver drug-metabolizing) enzymes. Selectivity is low, and human tissue distribution is uncharacterized. Critics argue these brief, low plasma levels leave unclear whether oral doses reach effective tissue concentrations.

  

## Historical Context & Evolution

PEA was first isolated in 1957 from egg yolk as the factor behind its anti-allergic effect in animals. Its original intended use was as a drug against respiratory infections: in the 1970s the Czechoslovak firm SPOFA marketed it as Impulsin, and six controlled trials in nearly 4,000 people reported fewer and milder colds and flu ([Keppel Hesselink et al., 2013](https://pubmed.ncbi.nlm.nih.gov/24066256/)). The product then faded from use without a published efficacy failure; the lack of a known mechanism is the usual explanation.

Interest returned in 1993, when Nobel laureate Rita Levi-Montalcini's group proposed that PEA restrains mast cells ([Aloe et al., 1993](https://pubmed.ncbi.nlm.nih.gov/7505999/)), and again in 2005, when PPAR-α was identified as its main receptor. In the following decade the Italian company Epitech developed micronized and ultramicronized forms, sold as foods for special medical purposes, and sponsored or supplied most pain trials. From 2019, Gencor, a Hong Kong ingredient maker, supplied a water-dispersible form for a series of Australian trials.

PEA came to be considered for health optimization because it is a natural body compound with a clean safety record that targets low-grade inflammation, a driver of age-related disease. Opinion has not settled: meta-analyses favor a pain benefit, while an independent 2016 appraisal flagged weak trial reporting and unknown absorption ([Gabrielsson et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27220803/)), and later independent trials added both positive and null results. Because PEA is unpatentable and not reimbursed by insurers, neither drug makers nor payers have an incentive to fund large trials, leaving supplement manufacturers as the main funders.

  

## Expected Benefits

<!-- Author statement on the search: Before writing this section, a dedicated search of the complete benefit profile was performed using PubMed (systematic reviews, randomized and controlled trials of palmitoylethanolamide, and searches on aging, sleep, cognition, infection, metabolism and exercise), ClinicalTrials.gov, the Examine and ConsumerLab summaries, the WebMD monograph and narrative reviews (Clayton 2021, Petrosino 2017, Bortoletto 2025). -->

### High 🟩 🟩 🟩

#### Chronic and Recurrent Pain Relief

PEA reduced pain across nerve, joint, back and menstrual pain in several meta-analyses; the largest pooled 18 randomized trials with 1,196 patients ([Viña & López-Moreno, 2025](https://pubmed.ncbi.nlm.nih.gov/39798151/)). Relief builds over 4–8 weeks, consistent with calming of nerve-adjacent immune cells. A 12-week trial in spinal cord injury pain found no benefit ([Andresen et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27227691/)). Much of the evidence comes from small Italian trials using Epitech products, and one pooled analysis was co-authored by Epitech staff ([Paladini et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26815246/)).

**Magnitude:** Standardized mean difference (SMD, a unit-free effect size where 0.8 is conventionally large) of 1.68 (95% CI, the range likely to contain the true effect, 1.05–2.31) versus comparators in double-blind trials ([Lang-Illievich et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36986081/)); about 2 points less pain on a 0–10 scale within the first month ([Schweiger et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38892586/)).

#### Fewer Upper Respiratory Infections

Taken daily as prevention, PEA lowered the number of colds and flu-like illnesses. In a 12-week trial of 426 healthy adults, 600 mg/day of the dispersible Levagen+ form reduced infection episodes and eased throat and cough symptoms ([Rao et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37892528/)); 1970s Czech trials in nearly 4,000 people reported similar protection ([Keppel Hesselink et al., 2013](https://pubmed.ncbi.nlm.nih.gov/24066256/)). The modern trial tested the manufacturer's (Gencor's) product at a contract research firm, and the older trials predate current reporting standards.

**Magnitude:** 39 versus 64 infection episodes over 12 weeks (about 39% fewer) ([Rao et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37892528/)); in three 1970s army trials, acute respiratory infections occurred in 10.6–22.7% with PEA versus 28.8–40.7% with placebo, as summarized in [the discussion of that 2023 trial report](https://pubmed.ncbi.nlm.nih.gov/37892528/).

#### Lower Eye Pressure in Glaucoma

In glaucoma (optic nerve damage often driven by raised eye pressure), oral PEA added to eye drops lowered intraocular pressure (IOP, the fluid pressure inside the eye), a validated risk marker for vision loss. A double-blind crossover trial (each patient received both treatments in turn) in 42 patients using timolol (a pressure-lowering eye drop) found a clear drop ([Gagliano et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21705689/)), and a meta-analysis confirmed the effect ([Crupi et al., 2025](https://pubmed.ncbi.nlm.nih.gov/38269580/)). Trials were small, Italian and did not measure vision outcomes.

**Magnitude:** IOP fell 3.5 mmHg (millimeters of mercury), or 15.9%, at 2 months versus 0.3 mmHg with placebo ([Gagliano et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21705689/)).

### Medium 🟩 🟩

#### Faster Relief of Depression Alongside Antidepressants

In 58 people with major depression, 600 mg twice daily of PEA added to citalopram (an SSRI, selective serotonin reuptake inhibitor, a standard antidepressant class) improved symptoms faster than citalopram alone over six weeks ([Ghazizadeh-Hashemi et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29486338/)). A diabetic nerve-pain trial also found lower depression scores ([Pickering et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36057884/)). The main trial was small, mostly male and short, and no trial has tested PEA alone for depression.

**Magnitude:** HAM-D (Hamilton Depression Rating Scale, a clinician-rated severity score) fell 8.3 versus 5.8 points by week 2; response rate 100% versus 74% at week 6 ([Ghazizadeh-Hashemi et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29486338/)).

#### Better Memory in Healthy Adults

In a six-week crossover trial of 39 healthy young adults, 700 mg/day of Levagen+ improved a paired-associates memory test and raised BDNF (brain-derived neurotrophic factor, a protein supporting nerve-cell growth) ([Kim et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38398813/)). Trials in people with cognitive decline mostly used PEA combined with luteolin (a plant flavonoid), so they do not isolate PEA ([Colizzi et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36387000/)). No trial has tested PEA alone in healthy older adults.

**Magnitude:** Memory errors fell with a moderate effect size (Cohen's d, a standardized effect size, of −0.47), and serum BDNF rose (d = 0.62) ([Kim et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38398813/)).

#### Lower Blood Triglycerides

In 58 adults with obesity, 700 mg/day of Levagen+ for 12 weeks lowered serum triglycerides (blood fats linked to heart disease) versus placebo, a secondary finding of a gut-microbiome trial ([Batacan et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39062193/)). PPAR-α activation, the pathway also used by fibrates (prescription triglyceride-lowering drugs), offers a plausible mechanism. The PEA group started with higher triglycerides, so part of the fall may reflect regression toward the average (the tendency of unusually high values to drift back toward typical levels on retesting).

**Magnitude:** −0.18 mmol/L (about −16 mg/dL) with PEA versus +0.07 mmol/L with placebo over 12 weeks ([Batacan et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39062193/)).

#### Eczema Relief With Topical Use

Applied to the skin twice daily for four weeks, a Levagen+ cream reduced redness, dryness and patient-rated eczema severity more than a standard moisturizer in 72 adults with atopic eczema ([Rao et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38408443/)). An older trial of a moisturizer combining PEA with N-acetylethanolamine in dry, itchy skin supports this ([Yuan et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25071367/)). The evidence applies to topical, not oral, use.

**Magnitude:** Total symptom score fell 56% with the PEA cream versus 30% with the comparator at week 4 ([Rao et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38408443/)).

#### Add-On Relief in Severe Psychiatric Disorders ⭕️ Not Central to Health & Longevity

Added to standard drugs, 600 mg twice daily of PEA improved negative symptoms of schizophrenia (withdrawal, flat emotion) ([Salehi et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35917650/)), manic symptoms in bipolar disorder ([Abedini et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35737597/)) and irritability in children with autism ([Khalaj et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29807317/)). Each finding rests on one small trial from the same Tehran research group. These results bear on treating established psychiatric illness rather than on health or longevity in well adults.

**Magnitude:** Irritability and hyperactivity in autism improved with a large effect size (Cohen's d 0.94) at week 10 ([Khalaj et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29807317/)).

### Low 🟩

#### Shorter Time to Fall Asleep ⚠️ Conflicted

In 103 poor sleepers, 350 mg/day of Levagen+ for 8 weeks shortened diary-reported sleep onset in those needing over 10 minutes to fall asleep ([Rao et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34522787/)). Wrist actigraphy (movement-based sleep tracking) and sleep quality showed no difference. Net reading: any benefit is small and objectively unconfirmed.

**Magnitude:** Diary sleep onset fell from 43 to 23 minutes with PEA versus 36 to 30 minutes with placebo in that subgroup ([Rao et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34522787/)).

#### Better Recovery of Smell After COVID-19

In a 185-patient randomized trial, a PEA–luteolin combination plus olfactory training (daily structured smelling exercises) restored smell better than training alone ([Di Stadio et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35450527/)). PEA was never tested alone for this, so its own contribution is indirect.

**Magnitude:** 92% of patients improved with the combination versus 42% with training plus placebo at 90 days ([Di Stadio et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35450527/)).

#### Seasonal Allergy Symptom Relief

In 108 adults with seasonal allergic rhinitis (pollen-triggered nasal allergy), 350 mg/day of Levagen+ for two weeks did not reduce nasal symptom scores overall; only a subgroup with mild-to-moderate symptoms improved, alongside lower histamine and inflammatory markers ([Briskey et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38068797/)). Such subgroup findings are exploratory.

**Magnitude:** No difference in total nasal symptom score across all participants; improvement appeared only in the subgroup scoring above 4 at baseline, for which the abstract reports no effect size ([Briskey et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38068797/)).

#### Faster Muscle Recovery After Exercise ⚠️ Conflicted

One trial found lower myoglobin and lactate (markers of muscle damage and fatigue) after leg-press exercise with Levagen+ ([Mallard et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32106527/)), but a later crossover trial found no effect on soreness, strength or jumping ([Schouten et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39086058/)). Net reading: no functional recovery benefit is established.

**Magnitude:** Strength losses of up to about 40% and jump-height losses of about 17% after eccentric (muscle-lengthening) exercise did not differ between PEA and placebo ([Schouten et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39086058/)).

#### Slower Parkinson's Disease Progression

In an uncontrolled study, 30 people with advanced Parkinson's disease who added 600 mg/day ultramicronized PEA to levodopa (the standard dopamine-replacing drug) showed falling symptom scores over a year ([Brotini et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28325153/)). In aged mice, PEA prevented toxin-induced Parkinson-like damage ([Crupi et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29552727/)). Placebo effects cannot be excluded.

**Magnitude:** Total MDS-UPDRS (the standard Parkinson's rating scale) score declined progressively over 12 months; without a control arm, the study reports no between-group outcome figure ([Brotini et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28325153/)).

### Speculative 🟨

#### Better Infection Survival in Old Age

Aged mice given PEA before a brain infection survived 18 hours longer and showed less harmful inflammation ([Heide et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30505308/)). No human data exist on infection outcomes in older adults.

#### Lower Systemic Inflammation

PEA lowered CRP (C-reactive protein, a general inflammation marker) and IL-6 (interleukin-6, an inflammatory messenger) in diabetic neuropathy ([Pickering et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36057884/)). These biomarkers are not validated surrogates for longevity outcomes.

  

## Benefit-Modifying Factors

* **Genetic polymorphisms:** No gene variant has been tested as a modifier of PEA response. A common FAAH variant (rs324420) slows breakdown of related messengers and could, in theory, alter PEA handling; PPARA (the gene encoding PPAR-α) variants are likewise unstudied.
* **Baseline biomarker levels:** Benefits appear largest where inflammation is present: elevated CRP and IL-6 fell in diabetic neuropathy ([Pickering et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36057884/)) and triglycerides fell in adults with obesity ([Batacan et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39062193/)). People with low baseline inflammation have little room to improve.
* **Sex differences:** A pooled pain analysis found response independent of sex ([Paladini et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26815246/)), the depression trial was mostly male ([Ghazizadeh-Hashemi et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29486338/)) and the menstrual-pain trial all female ([Rao et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39910730/)); no consistent sex-specific benefit pattern has emerged.
* **Pre-existing conditions:** Nerve-compression pain, knee osteoarthritis (wear-related joint disease) and diabetic neuropathy respond best in trials; spinal cord injury pain did not ([Andresen et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27227691/)). Glaucoma patients gain eye-pressure lowering; people without these conditions have fewer demonstrated benefits.
* **Age:** In N-of-1 trials (repeated single-patient crossover comparisons) in women averaging 83 years, only 2 of 10 showed a small pain benefit ([Germini et al., 2017](https://pubmed.ncbi.nlm.nih.gov/29210011/)); older adults may respond less, though they tolerated 1,200 mg/day.

  

## Potential Risks & Side Effects

<!-- Author statement on the search: Before writing this section, a dedicated search of the complete side-effect profile was performed using the WebMD drug monograph for palmitoylethanolamide (reviewed November 2025), adverse-event reporting in the randomized trials and meta-analyses cited in this review, PubMed searches for toxicology, genotoxicity and developmental toxicity, and the critical safety analysis by Gabrielsson et al. (2016). -->

### High 🟥 🟥 🟥

No risk reaches High: no adverse event has occurred significantly more often with PEA than with placebo in any controlled human trial.

### Medium 🟥 🟥

No risk reaches Medium: the only human adverse-event data are sporadic reports within small trials, without a significant excess over placebo in any single trial.

### Low 🟥

#### Mild Gastrointestinal Discomfort

Gastrointestinal discomfort is the most common adverse effect named in [a drug monograph](https://www.webmd.com/vitamins-supplements/palmitoylethanolamide), and nausea or loose stools appear sporadically in trials. In a 426-person trial, diarrhea was equally common with PEA and placebo ([Rao et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37892528/)). Symptoms are mild and reversible.

**Magnitude:** Diarrhea in 3 participants per group of about 210 ([Rao et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37892528/)); possibly product-related events (nausea, loose stools, restless sleep) in 3 of 36 PEA versus 0 of 22 placebo participants ([Batacan et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39062193/)).

#### Uncharacterized Long-Term or Rare Adverse Effects

Most trials last 2–12 weeks. An independent analysis found that existing data exclude common serious reactions only for courses up to about seven weeks ([Gabrielsson et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27220803/)). Rare or cumulative harms of multi-year use remain unknown.

**Magnitude:** Serious adverse reactions at a frequency of 1 in 200 or more are excluded for treatment up to 49 days; beyond 60 days, a frequency below 1 in 100 cannot be ruled out ([Gabrielsson et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27220803/)).

#### Unfavorable Metabolic Signal From High Body Levels

In 72 middle-aged adults, higher blood levels of the body's own PEA correlated with greater insulin resistance ([Rodríguez-García et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39636365/)). This is a cross-sectional association with natural levels, not a supplementation effect.

**Magnitude:** Correlation with HOMA-IR (homeostatic model assessment of insulin resistance, a fasting glucose–insulin index) of r (correlation coefficient) ≥ 0.32 ([Rodríguez-García et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39636365/)).

#### Allergic Reactions

[A drug monograph](https://www.webmd.com/vitamins-supplements/palmitoylethanolamide) lists hypersensitivity (allergic) reactions such as rash, hives or facial swelling as possible. Human evidence is limited to isolated reports; in a 426-person trial, one participant taking PEA developed a rash ([Rao et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37892528/)). Serious reactions have not been documented in trials.

**Magnitude:** One skin rash among about 210 PEA participants versus one skin irritation among about 210 placebo participants over 12 weeks ([Rao et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37892528/)).

### Speculative 🟨

#### Unknown Safety in Pregnancy and Breastfeeding

No human data exist. A rat study found no fetal harm at doses equivalent to over 9.7 g/day in humans ([Deshmukh et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33576293/)), but it was co-authored by Gencor staff.

#### Blunting of Useful Inflammation

Damping inflammation could theoretically weaken helpful signals, such as those driving training adaptation or infection clearance. The basis is mechanistic; one trial found no effect on muscle regeneration markers ([Schouten et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39086058/)).

  

## Risk-Modifying Factors

* **Genetic polymorphisms:** No pharmacogenetic interaction is known; PEA is not handled by CYP enzymes, so common CYP2D6 or CYP2C19 (liver drug-processing enzymes) variants are not expected to matter. The effect of FAAH variants on tolerability is unstudied.
* **Baseline biomarker levels:** People with high triglycerides, insulin resistance or raised liver enzymes have the most to watch for, given the observational insulin-resistance signal; trials found no changes in liver or safety blood tests.
* **Sex differences:** No sex-specific adverse events have been reported. For women who are or may become pregnant or are breastfeeding, human safety data are absent.
* **Pre-existing conditions:** Liver or kidney impairment, active gallbladder disease and immune suppression have not been studied; one trial participant with prior gallbladder problems reported recurrent cramps ([Batacan et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39062193/)). Multiple medications add uncertainty rather than known risk.
* **Age:** Adults averaging 83 years tolerated 1,200 mg/day in N-of-1 trials ([Germini et al., 2017](https://pubmed.ncbi.nlm.nih.gov/29210011/)); frail older adults with several chronic conditions remain understudied.
* **Combination products:** Added ingredients such as luteolin, polydatin or alpha-lipoic acid carry their own interaction and side-effect profiles.

  

## Key Interactions & Contraindications

* **Prescription pain medications:** NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen), opioids (strong narcotic pain-relieving drugs such as tramadol) and gabapentinoids (nerve-pain drugs such as pregabalin). Monitor: additive pain relief, possibly permitting dose reduction; no drug-handling interaction known. Mitigation: prescriber review after 4–8 weeks.
* **Psychiatric medications:** SSRIs (citalopram, sertraline), antipsychotics (drugs for psychosis such as risperidone) and lithium. Monitor: additive symptom effects in trials without excess side effects. Changes to psychiatric drugs belong with the prescriber; abrupt reductions risk relapse.
* **Glaucoma medications:** Beta-blocker drops (lower eye-fluid production; timolol) and prostaglandin analog drops (increase eye-fluid outflow; latanoprost). Monitor: additive eye-pressure lowering. Mitigation: eye-pressure check 1–2 months after starting PEA.
* **Fibrates:** Fibrates (fenofibrate, gemfibrozil) share the PPAR-α target. Caution, theoretical: additive triglyceride lowering and possible liver-enzyme rises. Mitigation: lipid panel and liver enzymes at 8–12 weeks.
* **Over-the-counter medications:** Analgesics (pain relievers such as acetaminophen, ibuprofen) and antihistamines (allergy drugs that block histamine, such as cetirizine, loratadine). Monitor: additive pain or allergy relief; no known harmful interaction. Mitigation: track use to judge whether PEA reduces need.
* **Supplements with additive effects:** Luteolin, polydatin, alpha-lipoic acid, acetyl-L-carnitine, CBD (cannabidiol, a hemp compound that inhibits FAAH and may raise PEA levels) and OEA (oleoylethanolamide, a related fatty amide). Monitor: additive anti-inflammatory and pain effects. Mitigation: introduce one at a time.
* **Other interventions:** Physical rehabilitation, olfactory training and cognitive behavioral therapy were combined with PEA in trials. Monitor: additive benefit reported, with no harm. Mitigation: keep existing therapy unchanged while assessing PEA.

**Populations who should avoid Palmitoylethanolamide:**

* Pregnant women in any trimester and breastfeeding women (no human safety data)
* People with known hypersensitivity to PEA or to product excipients (e.g., soy lecithin, gelatin)
* Children and adolescents under 18 years, outside a supervised clinical trial

  

## Risk Mitigation Strategies

* **Time-limited trial:** A defined 8-week trial at 600–1,200 mg/day, stopping if pain or target symptoms do not improve, limits exposure to the uncharacterized long-term risks.
* **Doses with meals:** Taking each dose with food containing fat, split into two daily doses, reduces nausea and loose stools.
* **Third-party tested products:** Choosing products verified by USP (United States Pharmacopeia), NSF International or ConsumerLab for identity and contaminants reduces risk from mislabeled or adulterated supplements.
* **Label check for combination products:** Confirming whether a product adds luteolin, polydatin or other agents prevents unintended exposure to their side effects and interactions.
* **Avoidance in pregnancy and breastfeeding:** Not using PEA while pregnant or breastfeeding avoids the unknown fetal and infant risk.
* **Stable prescription regimens:** Keeping analgesics and psychiatric drugs unchanged during the first 8 weeks prevents withdrawal or relapse; any reduction is made with the prescriber.
* **Periodic laboratory checks:** A lipid panel, fasting glucose and liver enzymes at 3 months, then every 6–12 months, detect any metabolic or liver signal during long-term use.

  

## Therapeutic Protocol

* **Italian ultramicronized regimen:** 600 mg twice daily for about 3 weeks, then 600 mg once daily for maintenance; developed with Epitech's products and popularized by Italian pain and rehabilitation clinicians ([Scaturro et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31863365/)).
* **Water-dispersible regimen:** 300–350 mg of Levagen+ once or twice daily (350–700 mg/day), the dosing used in Gencor-supplied trials, mostly run by RDC Clinical in Australia, for pain, sleep, infections and cognition.
* **Non-micronized regimen:** Jan Keppel Hesselink (Institute for Neuropathic Pain, Netherlands) popularized plain PEA, such as 400 mg PeaPure capsules, at about 1,200 mg/day in divided doses; no head-to-head trial shows any formulation to be superior.
* **Duration:** Pain trials show continued improvement between days 30 and 60; courses of at least 8 weeks are typical before judging response ([Schweiger et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38892586/)).
* **Time of day:** No study has compared dosing times. Trials split doses morning and evening; the sleep trial used a single daily dose ([Rao et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34522787/)).
* **Half-life:** Plasma levels return to baseline within about 4 hours of a dose, and rat data suggest a half-life near 12 minutes, though tissue effects likely outlast plasma levels.
* **Single versus split dosing:** The short plasma presence supports two or three divided daily doses rather than one large dose.
* **Genetic polymorphisms:** No variant, including FAAH, PPARA, APOE4 (the main genetic Alzheimer's risk variant) or MTHFR (a folate-processing enzyme), is known to warrant dose changes.
* **Sex differences:** Doses are identical for men and women; no sex-specific dosing has been studied.
* **Age:** Adults over 65 used the standard 1,200 mg/day without problems ([Germini et al., 2017](https://pubmed.ncbi.nlm.nih.gov/29210011/)), but may respond less, so response is typically judged over a longer 60-day window.
* **Baseline biomarker levels:** Higher baseline pain scores, CRP or eye pressure predict more room for measurable improvement; normal baselines make benefit harder to detect.
* **Pre-existing conditions:** Nerve-compression pain, osteoarthritis and diabetic neuropathy used 600–1,200 mg/day; glaucoma trials used 600 mg/day alongside eye drops ([Gagliano et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21705689/)). Spinal cord injury pain did not respond ([Andresen et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27227691/)).

  

## Discontinuation & Cycling

* **Duration of use:** PEA is typically used as a course of 2–6 months for a specific problem, or continued at a maintenance dose if benefit persists; no data cover lifelong use.
* **Withdrawal effects:** No withdrawal or rebound effects have been reported after stopping.
* **Tapering:** Not physiologically required; the Italian regimen's step-down from 1,200 to 600 mg/day serves as a maintenance taper rather than a safety measure.
* **Cycling:** No tolerance to PEA has been documented, and cycling has not been studied; periodic breaks mainly serve to test whether benefit continues.
* **Symptom return:** Pain or other target symptoms may gradually return after stopping; restarting the prior dose is the approach used in clinical practice.

  

## Sourcing and Quality

* **Formulations:** Plain PEA, micronized (m-PEA, roughly 2–10 µm particles), ultramicronized (um-PEA, under 2 µm; Normast) and water-dispersible (Levagen+, using LipiSperse technology) forms exist; only animal data compare their absorption directly.
* **Purity:** Supplement PEA is synthesized from palmitic acid and ethanolamine; quality products state at least 98% purity and supply a certificate of analysis for identity, heavy metals and residual solvents.
* **Third-party testing:** Verification by USP, NSF or ConsumerLab confirms label content and absence of contaminants; the FDA (US Food and Drug Administration) does not test supplements before sale.
* **Label dose:** Some labels state the weight of a formulated ingredient rather than of pure PEA; checking the PEA content per capsule avoids underdosing.
* **Reputable brands:** Normast (Epitech, Italy), PeaPure (JP Russell Science, Netherlands), Levagen+ (Gencor, an ingredient used by multiple brands) and Life Extension PEA are the most studied or widely distributed products.
* **Combination products:** Products such as Glialia (PEA with luteolin) and Pelvilen (PEA with polydatin) add a second active agent with its own evidence and risks.

  

## Practical Considerations

* **Time to effect:** Pain relief begins within 2–4 weeks and keeps building to about 60 days; eye-pressure lowering appears within one month ([Gagliano et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21705689/)); infection protection was measured over 12 weeks.
* **Common pitfalls:** Stopping before 8 weeks, taking PEA as an as-needed analgesic, buying combination products unknowingly and confusing it with phenylethylamine, a stimulant also sold as "PEA", are frequent mistakes.
* **Regulatory status:** Sold in the United States as a dietary supplement not approved by the FDA for any condition; in Italy as a food for special medical purposes; in Australia as a listed medicine ingredient (palmidrol).
* **Research funding:** Most trials were funded or supplied by Epitech or Gencor; because PEA is unpatentable and not reimbursed by insurers, independent large trials are scarce.
* **Cost and accessibility:** PEA is widely available online and in pharmacies at a modest monthly cost; it is neither exceptionally expensive nor difficult to obtain.

  

## Interaction with Foundational Habits

* **Sleep:** Potentiating but weak: one trial found faster sleep onset in poor sleepers without objective change ([Rao et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34522787/)). Proposed mechanism is endocannabinoid-related calming. No study has compared morning and evening dosing; one participant reported restless sleep ([Batacan et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39062193/)).
* **Nutrition:** Indirect: foods such as egg yolk, soybeans and peanuts supply only trace PEA. PEA is fat-soluble, so taking it with a fat-containing meal may aid absorption; no nutrient depletion is known. It complements anti-inflammatory eating patterns such as a Mediterranean diet.
* **Exercise:** None to slightly potentiating: a controlled trial found no effect on recovery from damaging exercise ([Schouten et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39086058/)). Unlike NSAIDs, no blunting of training adaptation has been shown. Exercise itself raises the body's endocannabinoid tone.
* **Stress management:** Indirect: anxiety scores fell in a knee osteoarthritis trial ([Steels et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30927159/)), but perceived stress did not change in adults with obesity ([Batacan et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39062193/)). Proposed mechanism involves PPAR-α and brain inflammation. No cortisol data exist.

  

## Monitoring Protocol & Defining Success

Baseline testing before starting establishes a reference point: a weekly-average pain score for the target problem, a metabolic panel with liver and kidney markers, a fasting lipid panel, fasting glucose with insulin, and high-sensitivity CRP. For people with glaucoma, baseline testing also includes an eye-pressure measurement by an eye specialist. Success is defined in advance, for example a pain reduction of at least 30%.

Ongoing monitoring follows at 4 weeks and 8–12 weeks, then every 6–12 months during continued use. At 4 weeks the check is symptom-based; at 8–12 weeks the laboratory panel is repeated to confirm safety and track triglycerides and inflammation. Eye pressure is rechecked 1–2 months after starting in glaucoma. If no meaningful benefit is seen by 8–12 weeks, the trial is considered unsuccessful.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| Pain intensity (0–10 NRS) | No established target; track change from own baseline, aiming for a reduction of at least 30% | Primary efficacy signal | NRS = numeric rating scale; record a weekly average at the same time of day |
| hs-CRP | Below 1.0 mg/L, ideally below 0.5 mg/L | Systemic inflammation | hs-CRP = high-sensitivity C-reactive protein; conventional low-risk cut-off is below 3.0 mg/L; avoid testing during acute illness |
| Triglycerides | Below 100 mg/dL (1.1 mmol/L) | Possible lowering by PEA; metabolic baseline | Conventional cut-off is below 150 mg/dL; 10–12 hour fast; pair with HDL (high-density lipoprotein) cholesterol |
| ALT and AST | Below 25 U/L each | Liver safety during long-term use | ALT = alanine aminotransferase, AST = aspartate aminotransferase (liver enzymes); conventional upper limits are about 40–55 U/L |
| Fasting glucose and HOMA-IR | Glucose 75–90 mg/dL; HOMA-IR below 1.5 | Watch the observational insulin-resistance signal | HOMA-IR = homeostatic model assessment of insulin resistance; conventional glucose limit is below 100 mg/dL; morning fasting sample |
| Intraocular pressure (glaucoma only) | Individual target set by the eye specialist, commonly 10–21 mmHg | Efficacy in glaucoma | Measured by tonometry (eye-pressure test); pressure varies over the day, so repeat at the same time |

Qualitative markers:

* Pain interference with daily activities, work and exercise
* Time to fall asleep and alertness on waking
* Mood and emotional resilience
* Frequency and severity of colds
* Digestive comfort after doses

  

## Emerging Research

* **Long-term safety:** A phase 2 placebo-controlled study of PEA in 200 healthy adults tracks serious adverse events over extended use ([NCT06717867](https://clinicaltrials.gov/study/NCT06717867)); run by RDC Clinical, which conducts manufacturer-supplied Levagen+ trials. It addresses the main safety gap for long-term users.
* **Chemotherapy nerve damage:** An independent phase 2 trial in 88 patients, with primary data collection completed in 2024 and registry results posted, found neither PEA dose better than placebo on the CIPN20 (chemotherapy-induced peripheral neuropathy questionnaire) ([NCT05246670](https://clinicaltrials.gov/study/NCT05246670)), a result that weakens nerve-pain claims.
* **Sleep and stress:** A four-arm phase 2 trial in 240 adults compares PEA, oleoylethanolamide, lavender oil and placebo on perceived stress, anxiety and sleep quality ([NCT07315516](https://clinicaltrials.gov/study/NCT07315516)); it could confirm or refute the weak sleep signal.
* **Brain protection in older adults:** A 100-patient study tests PEA with luteolin against postoperative cognitive decline in older adults undergoing cardiac surgery ([NCT07681063](https://clinicaltrials.gov/study/NCT07681063)); results will reflect the combination, not PEA alone.
* **Central sensitization in back pain:** A 106-patient study examines whether PEA reduces central sensitization (amplified pain processing in the nervous system) and inflammatory markers in chronic low back pain ([NCT07772141](https://clinicaltrials.gov/study/NCT07772141)).
* **Formulation comparisons:** No human head-to-head trial shows that micronized or dispersible PEA beats plain PEA ([Gabrielsson et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27220803/)); such trials could reshape dosing and product choice.
* **Independent null results:** Independent trials in spinal cord injury pain ([Andresen et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27227691/)) and exercise recovery ([Schouten et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39086058/)) found no benefit; further independent replications could narrow the benefit profile.
* **Healthy aging:** Aged-mouse studies suggest protection against infection and neurodegeneration ([Heide et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30505308/)), but no human study has examined healthspan or lifespan outcomes.

  

## Conclusion

Palmitoylethanolamide is a fatty messenger the body makes to calm local inflammation, now sold as an oral supplement. For health-focused adults, its clearest case is persistent pain: many trials against placebo and several analyses combining their results show meaningful relief that builds over one to two months, especially in nerve and joint pain. Evidence is also solid for fewer colds and for lower eye pressure in glaucoma. Faster mood improvement alongside antidepressants, sharper memory, lower blood fats and skin relief rest on single trials, while benefits for sleep, allergies, exercise recovery, Parkinson's disease and infection in old age remain weak, mixed or limited to animals. No human study has addressed lifespan or long-term healthy aging directly.

Its safety record is favorable. Side effects in trials were rare, mild and no more frequent than with placebo, and no drug interactions are known. Gaps remain: most studies ran only weeks, safety in pregnancy is unknown, and one study measuring the body's own levels, without supplementation, linked high levels to poorer blood sugar control.

The evidence base has clear limits. Most trials were small, and much of the research was funded, supplied or co-authored by the two main manufacturers, one in Italy and one in Hong Kong, which have a direct financial interest in favorable results. Because the compound cannot be patented and insurers do not pay for it, independent funding is scarce, so the evidence base reflects who pays for research as much as what the compound does.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**


